The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.

Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.

The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. Engineering T cells with this novel receptor engenders anti -gen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.

A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. Engineering T cells with this novel receptor engenders anti -gen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.

Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such PABPs and methods of making and using PABPs.

Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such PABPs and methods of making and using PABPs.